Maurie Markman


Challenges Arise as Public Health and Scientific Communication Enters Uncharted Territory

July 28th 2021

It is difficult to dispute that these are troubling times for government officials and public health agencies.

Patient Perspective Should Be Part of Assessing Value in Cancer Care

March 24th 2021

Costs associated with anticancer therapeutics continue to rise, although it also is recognized that the overall effectiveness of therapy has improved.

Dr. Markman on Privacy and Consent in Clinical Cancer Trials and Beyond

February 24th 2021

Maurie Markman, MD, discusses how privacy and consent in clinical cancer trials have improved over the years.

Pandemic Heightens Stress of Cancer Diagnosis

December 1st 2020

The repercussions of delays in diagnosing cancer, either through screening or the presence of early symptoms, and of required modifications in standard-of-care management paradigms in the COVID-19 era are only now beginning to be fully appreciated.

Innovations in the Management of Advanced Cervical Cancer: Focus on Multidisciplinary Care

November 16th 2020

The management of carcinoma of the cervix represents a remarkable dichotomy.

The Dilemma of New Evidence: When to Shift Gears

August 29th 2020

When is it appropriate to accept a specific strategy, either formally or informally, as a standard-of-care option in managing the treatment of patients with cancer in a particular clinical setting?

Dr. Markman on Timing of BSO in Patients With Ovarian Cancer

September 12th 2016

Maurie Markman, MD, president, Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses when patients with ovarian cancer should undergo a bilateral salpingo-oophorectomy (BSO).